LITTLE ROCK, Ark., Jan. 2, 2026 — Arkansas residents with severe obesity will soon have greater access to bariatric surgery, but not to the latest weight-loss drugs, under a new state law. Act 628, which took effect January 1, mandates that both Medicaid and commercial insurance plans cover bariatric surgery—including pre- and post-operative care—for individuals with a Body Mass Index (BMI) of 40 or higher, or a BMI of 35 or higher with related health conditions.
Surgery Gets a Second Look as Drug Costs Soar
The Arkansas law reflects a growing debate over the cost-effectiveness of different weight-loss treatments.
- Act 628 expands bariatric surgery coverage in Arkansas for those with severe obesity.
- The law explicitly excludes coverage for weight-loss injectable medications.
- The legislation comes as policymakers re-evaluate the financial sustainability of GLP-1 drugs.
While injectables are excluded from the requirements, bariatric surgery, once viewed as an “old-fashioned” method, is gaining renewed attention. “A handful of years ago, I never would have said this, but some people may need to consider—or we need to at least consider—the costs of surgical options,” said Kenny Bramwell, MD, Senior Medical Director at Select Health, at the Fall 2025 Payer Issues Roundtable. “Bariatric surgery suddenly seems inexpensive compared to $1,000 a month in perpetuity.”
What is the threshold for qualifying for bariatric surgery under the new Arkansas law? Individuals with a BMI greater than 40, or a BMI of 35 or higher with related health conditions, are eligible for coverage of bariatric surgery and associated care.
The shift in policy comes amid recent changes in coverage for GLP-1 medications and increased scrutiny of their long-term sustainability and health benefits. California Medicaid, for example, recently ended coverage for weight-loss drugs, signaling a broader trend of payers reassessing these costly treatments.
Did you know? Bariatric surgery has a long history as a treatment for severe obesity, but its popularity has waxed and waned over time, often overshadowed by newer pharmaceutical interventions.
The legislation highlights the complex economic considerations driving healthcare decisions, as insurers weigh the upfront costs of surgery against the ongoing expenses of prescription medications.
Related reading
